Cure My Disease

Don't miss your cure!

 Log in / Sign up

A Body-Scan test may reveal hidden fluid buildup, guiding early diuretic use

NCT ID NCT07801144

Disease control Sponsor: Kayseri Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This trial tests whether giving diuretics based on bioimpedance analysis, a body scan that measures fluid levels, can slow heart failure progression in people who have no visible signs of congestion. Participants are adults with heart failure and a reduced ejection fraction, but no symptoms of fluid overload, yet the scan shows excess fluid. Over one year, researchers compare those receiving bioimpedance-guided diuretics to those not taking diuretics, tracking changes in fluid status and heart function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Diuretic therapy guided by bioimpedance analysis measurements
What this could lead to
If it works, this could point toward a way to slow heart failure progression by treating hidden fluid overload earlier, potentially delaying the need for more intensive treatments.
What could go wrong
This is a small, early-stage study with 80 participants, so results may not apply broadly. Diuretics can cause side effects like dehydration or kidney issues, and the benefit over standard care is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

80 people

The number who actually took part.

Started

May 2019

Finished

Nov 2020

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients (aged 18 years and older) with a confirmed diagnosis of heart failure and a reduced left ventricular ejection fraction (LVEF \< 40%), who are routinely followed up or newly diagnosed at the internal medicine and cardiology outpatient clinics of Kayseri City Training and Research Hospital. Specifically, the cohort targets patients who do not exhibit obvious clinical signs of volume overload on standard physical examination (such as edema, hepatomegaly, or ascites) but are identified as hypervolemic based on objective bioimpedance analysis (overhydration value \> 0).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 years and older (regardless of gender) * Confirmed diagnosis of heart failure (newly diagnosed or previously under follow-up in the internal medicine or cardiology outpatient clinic) * Left ventricular ejection fraction (LVEF) \< 40% as determined by echocardiography * Patients who do not have hypervolemia detected on physical examination * Fluid volume status (overhydration \[OH\]) value greater than zero, as measured by bioimpedance analysis, thereby classifying them as hypervolemic for the study * Willingness to participate and ability to provide written informed consent prior to any study-related procedures Exclusion Criteria: * Patients under 18 years of age * Pregnant women * Patients with clinically evident decompensated heart failure requiring intravenous diuretic therapy * Presence of edema, hepatomegaly, or ascites upon physical examination

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Edema heart failure kidney failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

Contacts and locations

Locations

  • Kayseri City Hospital

    Kocasinan, Kayseri, 38020, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.